Use of immunomodulatory treatment for non-infectious uveitis: an International
Reviewed by Jonathan Chan

Two-hundred-and-twenty-one group members from 53 countries completed a questionnaire on their indications, investigations and use of conventional and biologics and follow-up of treated patients. Main indications to start systemic immunomodulatory drugs were: uveitis not controlled by oral prednisolone (94.1%), specific uveitis entity (89.1%), intolerance to oral prednisolone (84.2%). All members performed pretreatment screens including: blood chemistry, examination and quantiferon assay. Methotrexate (MTX) was the preferred conventional drug (57%) and for 9/11 uveitides; adalimumab (ADM) was the preferred biologics (97.7%) for 11/11 uveitides. The most popular combination was MTX plus ADM among the members (84%). Inactive uveitides were monitored and screened for drug toxicity every 6–12 weeks. The authors presented a useful practical guide for real-world application.

Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice.
Branford JA, Bodaghi B, Ferreira LB, et al.
British Journal of Ophthalmology
2025;109(4):482–9.